Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Glioma
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Receptor, Epidermal Growth Factor

abstract

  • Approximately 40% of human glioblastomas harbor oncogenic EGFR alterations, but attempts to therapeutically target EGFR with first-generation EGFR kinase inhibitors have failed. Here, we demonstrate selective sensitivity of glioma-specific EGFR mutants to ATP-site competitive EGFR kinase inhibitors that target the inactive conformation of the catalytic domain.

authors

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3354723

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-11-0284

PubMed ID

  • 22588883

Additional Document Info

start page

  • 458

end page

  • 71

volume

  • 2

number

  • 5